Acurian Eclipses 65 Million Records in Proprietary Patient Recruitment Database

HORSHAM, Pa. , February 08 /Businesswire/ - Acurian, Inc., a leading, full-service provider of patient recruitment and retention solutions, announced today that its patient recruitment database now contains over 65 million records, or 49% of the estimated 133 million Americans with a chronic disease.

According to Rick Malcolm, Acurian’s CEO, the company first built the database in 1998 and has increased its size, targeting capabilities and efficiency over the last decade.

“The Acurian patient recruitment database is well known in the clinical trial industry as the gold standard for direct-to-patient and direct-to-caregiver access,” stated Malcolm. “We can launch highly targeted patient recruitment campaigns in weeks, and our data and patient processes meet the highest standards of privacy protection.”

Acurian maintains a staff of full-time data analysts and modelers who develop objective clinical feasibility and enrollment projections using metrics from previous projects and third-party therapeutic data. This enables the company to deploy its full range of in-house service offerings, not just the patient recruitment database, to ensure biopharmaceutical and medical device companies meet or beat their enrollment timelines.

In addition to the patient recruitment database, Acurian sources clinical trial participants via centralized advertising, online health and social networks, improved site selection services, and a wide variety of other tactics. Most services are delivered under performance-based contracts.

About Acurian

Acurian is a leading full-service provider of clinical trial patient recruitment and retention solutions for the life sciences industry. Through its proprietary patient panel of over 65 million patients, centralized advertising capabilities, and a fully hosted enrollment management technology platform, Acurian is able to identify, contact, prescreen, and refer patients into clinical trials, all while supporting investigator sites with services to maximize the randomization potential of every referred patient. Since 1998, Acurian has supported over 400 protocols for more than 60 companies. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures.